World Diabetes Day to focus on women at risk for, living with diabetes

The International Diabetes Federation is marking World Diabetes Day on Tuesday with a campaign that will promote for all women at risk for or living with diabetes the affordable and fair access to necessary medications, technologies, self-management education and information, according to the International Diabetes Federation website.

The AMA recently announced a multi-state effort to reduce the incidence of type 2 diabetes nationwide.

“With 90% of the people living with prediabetes in this country unaware they have the condition and at high risk for developing type 2 diabetes, we are excited to now be working with eight new states to help reach thousands more patients with prediabetes,” David O. Barbe, MD, president of AMA, said in a press release. “Using what we’ve learned through our ongoing work, we will have more opportunities to get more patients into proven programs that can help prevent or delay the onset of type 2 diabetes.”

Endocrine Today has compiled a list of the top 10 diabetes news stories posted online from September to World Diabetes Day.

Healio.com/Endocrinology readers were interested in diabetes care after Hurricane Harvey, updated prescribing information for an inhaled insulin, and much more.

In Hurricane Harvey’s wake, endocrinologists, CDEs work together to meet diabetes supply crisis in Houston

As Hurricane Harvey slowly made its way out of the greater Houston area after dumping unprecedented amounts of rainfall in the region, pleas from affected residents with type 1 and type 2 diabetes have grown increasingly desperate, according to an area endocrinologist. Read more.

FDA updates prescribing information for Afrezza

The FDA recently approved updated prescribing information for the only available inhaled insulin powder to include new clinical data that was presented at the American Diabetes Associations’ Scientific Sessions in 2016, according to a release from MannKind Corporation. Read more.

DEVOTE: Hypoglycemia, glycemic variability increase mortality risk in type 2 diabetes

In adults with type 2 diabetes, higher day-to-day fasting glycemic variability and severe hypoglycemia are independently associated with all-cause mortality, according to two secondary analyses from the DEVOTE trial presented at the European Association for the Study of Diabetes Annual Meeting and published simultaneously in Diabetologia. Read more.

Global disease burden reveals deaths from diabetes increasing

Deaths from diabetes have risen more than 30% over the past decade, and poor diet was associated with almost 20% of all deaths, according to the latest global estimates for the state of the world’s health, recently published in The Lancet. Read more.

Under-skin islet cell transplantation may provide new option for type 1 diabetes

Researchers from the University of Toronto are transplanting pancreatic islet cells subcutaneously as a treatment for type 1 diabetes, according to a press release from the University of Toronto Faculty of Applied Science and Engineering. Read more.

FDA approves once-weekly exenatide extended-release injection

The FDA recently approved AstraZeneca’s GLP-1 receptor agonist exenatide extended-release injection in a once-weekly single-dose autoinjector device for the treatment of adults with type 2 diabetes, according to a press release from AstraZeneca. Read more.

Experimental oral diabetes drug appears safe, effective in Japanese adults

Imeglimin, part of a new class of oral agents for type 2 diabetes that target mitochondrial bioenergetics, was found to be safe and effective in Japanese adults, according to results presented at the European Association for the Study of Diabetes Annual Meeting. Read more.

Sotagliflozin effectively reduces HbA1c in type 1 diabetes

Sotagliflozin, an SGLT1 and SGLT2 inhibitor, was more effective than placebo for reducing HbA1c in adults with type 1 diabetes who were receiving insulin therapy, but the rates of diabetic ketoacidosis were higher with sotagliflozin than with placebo, according to findings from the inTandem3 study presented at the European Association for the Study of Diabetes Annual Meeting and published simultaneously in The New England Journal of Medicine. Read more.

Biomarker may predict preeclampsia risk in women with type 1 diabetes

Pregnancy outcomes in women with childhood-onset type 1 diabetes are commonly poor, and a new biomarker could help predict which women may develop preeclampsia, according to two studies presented at the European Association for the Study of Diabetes Annual Meeting. Read more.

FDA review supports safety, efficacy claims for semaglutide

A preliminary review by the FDA states that the GLP-1 receptor agonist semaglutide is safe and effective for the indication of improving glycemic control in adults with type 2 diabetes, according to a briefing document released by the agency this week. Read more.

For more information on World Diabetes Day visit: http://www.worlddiabetesday.org/about-wdd/wdd-2017.html

 

The International Diabetes Federation is marking World Diabetes Day on Tuesday with a campaign that will promote for all women at risk for or living with diabetes the affordable and fair access to necessary medications, technologies, self-management education and information, according to the International Diabetes Federation website.

The AMA recently announced a multi-state effort to reduce the incidence of type 2 diabetes nationwide.

“With 90% of the people living with prediabetes in this country unaware they have the condition and at high risk for developing type 2 diabetes, we are excited to now be working with eight new states to help reach thousands more patients with prediabetes,” David O. Barbe, MD, president of AMA, said in a press release. “Using what we’ve learned through our ongoing work, we will have more opportunities to get more patients into proven programs that can help prevent or delay the onset of type 2 diabetes.”

Endocrine Today has compiled a list of the top 10 diabetes news stories posted online from September to World Diabetes Day.

Healio.com/Endocrinology readers were interested in diabetes care after Hurricane Harvey, updated prescribing information for an inhaled insulin, and much more.

In Hurricane Harvey’s wake, endocrinologists, CDEs work together to meet diabetes supply crisis in Houston

As Hurricane Harvey slowly made its way out of the greater Houston area after dumping unprecedented amounts of rainfall in the region, pleas from affected residents with type 1 and type 2 diabetes have grown increasingly desperate, according to an area endocrinologist. Read more.

FDA updates prescribing information for Afrezza

The FDA recently approved updated prescribing information for the only available inhaled insulin powder to include new clinical data that was presented at the American Diabetes Associations’ Scientific Sessions in 2016, according to a release from MannKind Corporation. Read more.

DEVOTE: Hypoglycemia, glycemic variability increase mortality risk in type 2 diabetes

In adults with type 2 diabetes, higher day-to-day fasting glycemic variability and severe hypoglycemia are independently associated with all-cause mortality, according to two secondary analyses from the DEVOTE trial presented at the European Association for the Study of Diabetes Annual Meeting and published simultaneously in Diabetologia. Read more.

Global disease burden reveals deaths from diabetes increasing

Deaths from diabetes have risen more than 30% over the past decade, and poor diet was associated with almost 20% of all deaths, according to the latest global estimates for the state of the world’s health, recently published in The Lancet. Read more.

PAGE BREAK

Under-skin islet cell transplantation may provide new option for type 1 diabetes

Researchers from the University of Toronto are transplanting pancreatic islet cells subcutaneously as a treatment for type 1 diabetes, according to a press release from the University of Toronto Faculty of Applied Science and Engineering. Read more.

FDA approves once-weekly exenatide extended-release injection

The FDA recently approved AstraZeneca’s GLP-1 receptor agonist exenatide extended-release injection in a once-weekly single-dose autoinjector device for the treatment of adults with type 2 diabetes, according to a press release from AstraZeneca. Read more.

Experimental oral diabetes drug appears safe, effective in Japanese adults

Imeglimin, part of a new class of oral agents for type 2 diabetes that target mitochondrial bioenergetics, was found to be safe and effective in Japanese adults, according to results presented at the European Association for the Study of Diabetes Annual Meeting. Read more.

Sotagliflozin effectively reduces HbA1c in type 1 diabetes

Sotagliflozin, an SGLT1 and SGLT2 inhibitor, was more effective than placebo for reducing HbA1c in adults with type 1 diabetes who were receiving insulin therapy, but the rates of diabetic ketoacidosis were higher with sotagliflozin than with placebo, according to findings from the inTandem3 study presented at the European Association for the Study of Diabetes Annual Meeting and published simultaneously in The New England Journal of Medicine. Read more.

Biomarker may predict preeclampsia risk in women with type 1 diabetes

Pregnancy outcomes in women with childhood-onset type 1 diabetes are commonly poor, and a new biomarker could help predict which women may develop preeclampsia, according to two studies presented at the European Association for the Study of Diabetes Annual Meeting. Read more.

FDA review supports safety, efficacy claims for semaglutide

A preliminary review by the FDA states that the GLP-1 receptor agonist semaglutide is safe and effective for the indication of improving glycemic control in adults with type 2 diabetes, according to a briefing document released by the agency this week. Read more.

For more information on World Diabetes Day visit: http://www.worlddiabetesday.org/about-wdd/wdd-2017.html